Themis Medicare Limited (THEMISMED.NS)
INR 123.32
(6.39%)
INR 123.32
(6.39%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 764.96 Million INR | -4.17% |
| 2022 | 798.28 Million INR | 34.27% |
| 2021 | 594.53 Million INR | -12.78% |
| 2020 | 681.64 Million INR | -29.44% |
| 2019 | 966.01 Million INR | 20.68% |
| 2018 | 800.48 Million INR | 6.0% |
| 2017 | 755.14 Million INR | -28.25% |
| 2016 | 1.05 Billion INR | 6.65% |
| 2015 | 986.91 Million INR | -17.77% |
| 2014 | 1.2 Billion INR | -4.01% |
| 2013 | 1.25 Billion INR | -4.23% |
| 2012 | 1.3 Billion INR | 125.02% |
| 2011 | 580.18 Million INR | -49.86% |
| 2010 | 1.15 Billion INR | 6.76% |
| 2009 | 1.08 Billion INR | -2.64% |
| 2008 | 1.11 Billion INR | 22.02% |
| 2007 | 912.42 Million INR | 34.53% |
| 2006 | 678.22 Million INR | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | 99.25 Million INR | -87.03% |
| 2024 Q2 | 717.54 Million INR | 622.97% |
| 2023 Q1 | 188.85 Million INR | -76.34% |
| 2023 Q3 | 223.83 Million INR | -72.4% |
| 2023 FY | 764.96 Million INR | -4.17% |
| 2023 Q4 | 764.96 Million INR | 241.76% |
| 2023 Q2 | 811.07 Million INR | 329.47% |
| 2022 Q3 | 184.8 Million INR | -70.9% |
| 2022 Q2 | 634.95 Million INR | 139.61% |
| 2022 Q1 | 264.99 Million INR | -55.43% |
| 2022 FY | 798.28 Million INR | 34.27% |
| 2022 Q4 | 798.28 Million INR | 331.97% |
| 2021 Q4 | 594.53 Million INR | 131.43% |
| 2021 Q3 | 256.89 Million INR | -49.7% |
| 2021 Q2 | 510.68 Million INR | 107.31% |
| 2021 Q1 | 246.33 Million INR | -63.86% |
| 2021 FY | 594.53 Million INR | -12.78% |
| 2020 Q2 | 752.66 Million INR | 1321.52% |
| 2020 Q1 | 52.94 Million INR | -94.52% |
| 2020 FY | 681.64 Million INR | -29.44% |
| 2020 Q4 | 681.64 Million INR | 488.78% |
| 2020 Q3 | 115.77 Million INR | -84.62% |
| 2019 Q1 | 17.58 Million INR | -97.8% |
| 2019 Q2 | 751.3 Million INR | 4173.61% |
| 2019 FY | 966.01 Million INR | 20.68% |
| 2019 Q3 | 50.75 Million INR | -93.24% |
| 2019 Q4 | 966.01 Million INR | 1803.15% |
| 2018 Q1 | 44.96 Million INR | -94.05% |
| 2018 Q4 | 800.48 Million INR | 0.0% |
| 2018 FY | 800.48 Million INR | 6.0% |
| 2017 FY | 755.14 Million INR | -28.25% |
| 2017 Q4 | 755.14 Million INR | 830.32% |
| 2017 Q1 | 101.33 Million INR | -88.15% |
| 2017 Q3 | 81.17 Million INR | -87.35% |
| 2017 Q2 | 641.8 Million INR | 533.34% |
| 2016 Q4 | 855.23 Million INR | 386.88% |
| 2016 Q1 | 148.51 Million INR | -84.95% |
| 2016 FY | 1.05 Billion INR | 6.65% |
| 2016 Q2 | 863.19 Million INR | 481.23% |
| 2016 Q3 | 175.65 Million INR | -79.65% |
| 2015 FY | 986.91 Million INR | -17.77% |
| 2015 Q4 | 986.91 Million INR | 763.83% |
| 2015 Q3 | 114.24 Million INR | -89.94% |
| 2015 Q2 | 1.13 Billion INR | 1206.45% |
| 2015 Q1 | 86.92 Million INR | -92.76% |
| 2014 Q4 | 1.2 Billion INR | 0.0% |
| 2014 FY | 1.2 Billion INR | -4.01% |
| 2013 FY | 1.25 Billion INR | -4.23% |
| 2012 Q4 | 1.3 Billion INR | 0.0% |
| 2012 Q2 | 1.17 Billion INR | 0.0% |
| 2012 FY | 1.3 Billion INR | 125.02% |
| 2011 FY | 580.18 Million INR | -49.86% |
| 2010 FY | 1.15 Billion INR | 6.76% |
| 2009 FY | 1.08 Billion INR | -2.64% |
| 2008 FY | 1.11 Billion INR | 22.02% |
| 2007 FY | 912.42 Million INR | 34.53% |
| 2006 FY | 678.22 Million INR | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Alembic Pharmaceuticals Limited | 3.86 Billion INR | 80.213% |
| Hester Biosciences Limited | 2.29 Billion INR | 66.606% |
| Aarti Drugs Limited | 5.54 Billion INR | 86.213% |
| Aarti Pharmalabs Limited | 2.61 Billion INR | 70.712% |
| Albert David Limited | -278.36 Million INR | 374.801% |
| Alembic Limited | 66.9 Million INR | -1043.441% |
| Alkem Laboratories Limited | -1.6 Billion INR | 147.531% |
| Bafna Pharmaceuticals Limited | 229.93 Million INR | -232.689% |
| Bajaj HealthCare Limited | 3.29 Billion INR | 76.812% |
| Biofil Chemicals and Pharmaceuticals Limited | -18.44 Million INR | 4247.035% |
| Brooks Laboratories Limited | 49.48 Million INR | -1445.846% |
| Eris Lifesciences Limited | 13.8 Billion INR | 94.459% |
| FDC Limited | -57.75 Million INR | 1424.564% |
| Glenmark Life Sciences Limited | -2.84 Billion INR | 126.91% |
| Gufic Biosciences Limited | 3.19 Billion INR | 76.052% |
| Hikal Limited | 7.96 Billion INR | 90.398% |
| Ind-Swift Limited | 9.5 Billion INR | 91.955% |
| Innova Captab Limited | 2.33 Billion INR | 67.222% |
| IOL Chemicals and Pharmaceuticals Limited | -1.1 Billion INR | 169.46% |
| Jagsonpal Pharmaceuticals Limited | -1.38 Billion INR | 155.036% |
| Jubilant Pharmova Limited | 27.07 Billion INR | 97.174% |
| Lincoln Pharmaceuticals Limited | -127.63 Million INR | 699.322% |
| Lupin Limited | 19.38 Billion INR | 96.054% |
| Mangalam Drugs & Organics Limited | 975.81 Million INR | 21.608% |
| Medico Remedies Limited | 78.67 Million INR | -872.282% |
| Morepen Laboratories Limited | -231.17 Million INR | 430.903% |
| Nectar Lifesciences Limited | 6.15 Billion INR | 87.576% |
| Orchid Pharma Limited | -1.31 Billion INR | 158.223% |
| Procter & Gamble Health Limited | -2.34 Billion INR | 132.579% |
| RPG Life Sciences Limited | -364.7 Million INR | 309.751% |
| Kilitch Drugs (India) Limited | 120.03 Million INR | -537.261% |
| Sigachi Industries Limited | 859.94 Million INR | 11.046% |
| Solara Active Pharma Sciences Limited | 10.03 Billion INR | 92.375% |
| Suven Pharmaceuticals Limited | 144.97 Million INR | -427.647% |
| Unichem Laboratories Limited | 931.91 Million INR | 17.915% |
| Vaishali Pharma Limited | 119.13 Million INR | -542.097% |
| Wanbury Limited | 1.1 Billion INR | 30.827% |
| Windlas Biotech Limited | -273.04 Million INR | 380.165% |
| ZIM Laboratories Limited | 983.6 Million INR | 22.229% |
| Ind-Swift Laboratories Limited | -4.15 Billion INR | 118.419% |
| Ipca Laboratories Limited | 11.41 Billion INR | 93.299% |
| Sun Pharmaceutical Industries Limited | -72.47 Billion INR | 101.056% |
| Venus Remedies Limited | -267.7 Million INR | 385.753% |
| Sakar Healthcare Limited | 790.93 Million INR | 3.284% |
| Aurobindo Pharma Limited | 3.69 Billion INR | 79.288% |
| Divi's Laboratories Limited | -39.77 Billion INR | 101.923% |
| AstraZeneca Pharma India Limited | -5.01 Billion INR | 115.261% |
| Mankind Pharma Limited | -1.74 Billion INR | 143.753% |
| Sequent Scientific Limited | 4.17 Billion INR | 81.693% |
| Laurus Labs Limited | 24.35 Billion INR | 96.859% |
| Neuland Laboratories Limited | -214.05 Million INR | 457.362% |
| J. B. Chemicals & Pharmaceuticals Limited | 2.82 Billion INR | 72.885% |
| Glenmark Pharmaceuticals Limited | -4.28 Billion INR | 117.851% |
| Zydus Lifesciences Limited | 3.91 Billion INR | 80.446% |
| Amrutanjan Health Care Limited | -248.79 Million INR | 407.47% |
| Wockhardt Limited | 18.27 Billion INR | 95.813% |
| Bal Pharma Limited | 1.26 Billion INR | 39.46% |
| Dr. Reddy's Laboratories Limited | 12.91 Billion INR | 94.076% |
| Bliss GVS Pharma Limited | -1.15 Billion INR | 166.073% |
| Par Drugs and Chemicals Limited | -366.53 Million INR | 308.699% |
| Caplin Point Laboratories Limited | -5.5 Billion INR | 113.889% |
| Shilpa Medicare Limited | 9.06 Billion INR | 91.566% |
| Valiant Laboratories Limited | 649.9 Million INR | -17.704% |
| Ajanta Pharma Limited | -954.9 Million INR | 180.109% |
| Aarey Drugs & Pharmaceuticals Limited | 297.57 Million INR | -157.062% |
| Granules India Limited | 9.28 Billion INR | 91.763% |
| Medicamen Biotech Limited | 160.31 Million INR | -377.159% |
| Syncom Formulations (India) Limited | 46.21 Million INR | -1555.368% |
| Piramal Enterprises Limited | 491.39 Billion INR | 99.844% |
| Torrent Pharmaceuticals Limited | 31.83 Billion INR | 97.597% |
| NATCO Pharma Limited | -5.81 Billion INR | 113.15% |
| Suven Life Sciences Limited | -1.63 Billion INR | 146.853% |
| Krebs Biochemicals & Industries Limited | 1.93 Billion INR | 60.425% |
| Strides Pharma Science Limited | 23.25 Billion INR | 96.711% |
| Indoco Remedies Limited | 6.47 Billion INR | 88.188% |
| Alpa Laboratories Limited | 35.36 Million INR | -2063.171% |
| Lasa Supergenerics Limited | 205.79 Million INR | -271.703% |
| Sun Pharma Advanced Research Company Limited | -941.8 Million INR | 181.223% |